SCHEMBL23249804

SCHEMBL23249804

Cc1ccc(O)c(=O)c(-c2cncc(F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 1/20 0.43
▸ PARP11 Q9NR21 1/20 0.43
▸ IDO1 P14902 1/20 0.41
▸ CYP11B2 P19099 5/20 0.41
▸ CYP11B1 P15538 3/20 0.41
▸ CYP17A1 P05093 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ ALOX15 P16050 3/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ TP53 P04637 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29890183 1.00 PARP10 (0.43) PARP10PARP11IDO1CYP11B2CYP11B1
SCHEMBL27018669 0.85 PARP10 (0.45) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL29891580 0.82 RNASEH1 (0.42) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL23249826 0.82 RNASEH1 (0.42) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL29890460 0.80 CYP11B2 (0.43) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL23249822 0.80 CYP11B2 (0.43) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL26948394 0.78 PARP10 (0.43) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL23263178 0.78 CYP11B2 (0.43) PARP10PARP11CYP11B2CYP11B1
SCHEMBL26950330 0.76 PARP10 (0.42) PARP10PARP11CYP11B2CYP11B1CYP17A1
SCHEMBL29890214 0.73 PARP10 (0.43) PARP10PARP11CYP11B2CYP11B1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073131-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) 2024-04-04 — — WO disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
EP-4045025-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 — — EP disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB PARP10 2741/4885PARP11 3002/4885IDO1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback